Sarepta Therapeutics Management
Management criteria checks 2/4
Sarepta Therapeutics' CEO is Doug Ingram, appointed in Jun 2017, has a tenure of 6.83 years. total yearly compensation is $124.94M, comprised of 0.6% salary and 99.4% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $45.49M. The average tenure of the management team and the board of directors is 3.3 years and 7.9 years respectively.
Key information
Doug Ingram
Chief executive officer
US$124.9m
Total compensation
| CEO salary percentage | 0.6% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.3yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15
Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
Feb 09Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Feb 07A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Dec 06Sarepta: Revenue Keeps Rising While We Wait For Functional Data
Nov 01Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?
Nov 01Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Jul 19Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed
Jun 02Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation
May 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
| Sep 30 2019 | n/a | n/a | -US$620m |
| Jun 30 2019 | n/a | n/a | -US$570m |
| Mar 31 2019 | n/a | n/a | -US$403m |
| Dec 31 2018 | US$1m | US$650k | -US$362m |
| Sep 30 2018 | n/a | n/a | -US$245m |
| Jun 30 2018 | n/a | n/a | -US$216m |
| Mar 31 2018 | n/a | n/a | -US$170m |
| Dec 31 2017 | US$57m | US$338k | -US$51m |
Compensation vs Market: Doug's total compensation ($USD124.94M) is above average for companies of similar size in the US market ($USD13.41M).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
CEO
Doug Ingram (60 yo)
6.8yrs
Tenure
US$124,938,694
Compensation
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$124.94m | 0.42% $ 45.5m | |
| Executive VP & CFO | 3.3yrs | US$3.82m | 0.039% $ 4.2m | |
| Executive VP | 3.3yrs | US$3.94m | 0.073% $ 7.9m | |
| Executive VP | 3.3yrs | US$3.73m | 0.031% $ 3.3m | |
| Executive VP & Chief Technical Operations Officer | 1.3yrs | no data | 0.027% $ 2.9m | |
| Executive Director of Investor Relations and Corporate Communications | no data | no data | no data | |
| Executive VP & Chief People Officer | 2.5yrs | no data | no data | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 4.6yrs | no data | no data | |
| Executive VP & Chief Customer Officer | 3.3yrs | no data | no data | |
| Senior VP | 1.3yrs | no data | no data | |
| Controller & VP | 7.1yrs | US$911.89k | no data | |
| Senior Manager of Investor Relations | no data | no data | no data |
3.3yrs
Average Tenure
49yo
Average Age
Experienced Management: SRPT's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$124.94m | 0.42% $ 45.5m | |
| Independent Chairwoman | 15.1yrs | US$594.35k | 0.20% $ 21.4m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 13.8yrs | US$546.35k | 0.022% $ 2.4m | |
| Independent Director | 8.8yrs | US$562.35k | 3.39% $ 370.4m | |
| Member of Strategic & Scientific Advisory Board | 8.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.4yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 8.7yrs | no data | no data | |
| Independent Non-Employee Director | 8.8yrs | US$553.35k | 0.016% $ 1.7m | |
| Member of Strategic & Scientific Advisory Board | 7.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 7.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.4yrs | no data | no data |
7.9yrs
Average Tenure
70yo
Average Age
Experienced Board: SRPT's board of directors are considered experienced (7.9 years average tenure).